Interim results from 50 patients at 24 months in the EVoluSIon study, assessing RTI Surgical’s SImmetry® sacroiliac fusion system, indicate that 98% of treated joints show evidence of fusion with 78% of patients remaining opioid-free. Of the 98% of treated joints with evidence of fusion, 84% showed solid fusion and 14% possible fusion.
“Interim EVoluSIon study data continue to show that joint decortication as part of the SImmetry System helps to achieve real fusion, which supports reduced opioid use and significant pain relief,” said Camille Farhat, President and CEO, RTI Surgical. “As we progress toward our future as a more focused spine company, RTI is committed to offering surgeons a growing portfolio of differentiated clinical solutions and therapies backed by data to deliver better outcomes for patients.”
At the start of 2020, the company announced a definitive agreement to divest its OEM business to a European private equity firm.
Interim results from 50 patients at 24 months in the EVoluSIon study, assessing RTI Surgical's SImmetry® sacroiliac fusion system, indicate that 98% of treated joints show evidence of fusion with 78% of patients remaining opioid-free. Of the 98% of treated joints with evidence of fusion, 84% showed solid fusion and 14% possible fusion.
The...
Interim results from 50 patients at 24 months in the EVoluSIon study, assessing RTI Surgical’s SImmetry® sacroiliac fusion system, indicate that 98% of treated joints show evidence of fusion with 78% of patients remaining opioid-free. Of the 98% of treated joints with evidence of fusion, 84% showed solid fusion and 14% possible fusion.
“Interim EVoluSIon study data continue to show that joint decortication as part of the SImmetry System helps to achieve real fusion, which supports reduced opioid use and significant pain relief,” said Camille Farhat, President and CEO, RTI Surgical. “As we progress toward our future as a more focused spine company, RTI is committed to offering surgeons a growing portfolio of differentiated clinical solutions and therapies backed by data to deliver better outcomes for patients.”
At the start of 2020, the company announced a definitive agreement to divest its OEM business to a European private equity firm.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
